Who are Euvichol-S Oral Cholera Vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Trivalent OPV 4 week interval.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/euvichol-s-oral-cholera-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Euvichol-S Oral Cholera Vaccine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Euvichol-S Oral Cholera Vaccine (Euvichol-S Oral Cholera Vaccine) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated oral vaccine. Area: Infectious Disease / Immunology.

marketed Live attenuated oral vaccine Infectious Disease / Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Euvichol-S Oral Cholera Vaccine (Euvichol-S Oral Cholera Vaccine) — Albert B. Sabin Vaccine Institute. Euvichol-S is a live attenuated oral cholera vaccine that stimulates mucosal and systemic immune responses against Vibrio cholerae.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Euvichol-S Oral Cholera Vaccine TARGET	Euvichol-S Oral Cholera Vaccine	Albert B. Sabin Vaccine Institute	marketed	Live attenuated oral vaccine
Trivalent OPV 4 week interval	Trivalent OPV 4 week interval	International Centre for Diarrhoeal Disease Research, Bangladesh	marketed	Live attenuated oral vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated oral vaccine class)

Albert B. Sabin Vaccine Institute · 1 drug in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Euvichol-S Oral Cholera Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/euvichol-s-oral-cholera-vaccine. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab